The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, noncomparative, open label, multicentre, study of AZD9291 in patients with locally advanced or metastatic EGFR mutated “T790M undetectable or unknown” non-small cell lung cancer (stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study).
 
Hector J. Soto Parra
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly
 
Laura Noto
No Relationships to Disclose
 
Domenico Galetta
No Relationships to Disclose
 
Francesco Ferraú
No Relationships to Disclose
 
Vittorio Gebbia
No Relationships to Disclose
 
Pierfrancesco Tassone
No Relationships to Disclose
 
Francesco Verderame
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Marco M. Aiello
No Relationships to Disclose
 
Fiorenza Latteri
No Relationships to Disclose
 
Silvia Novello
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche